United Health Products (UEEC) Form 3/A United Health Products / Kristofer Heaton ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Heaton Kristofer

(Last) (First) (Middle)

10624 SOUTH EASTERN AVE.

SUITE A209

(Street)

HENDERSON NV 89052

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/01/2020

3. Issuer Name and Ticker or Trading Symbol
United Health Products, Inc. [ UEEC ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Principal Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)
12/08/2020

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock(1)	305,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit Awards	(2)	(2)	Common Stock	425,000	(2)	D

Explanation of Responses:

1. Excludes restricted stock unit awards totaling 425,000 shares.

2. The restricted stock unit awards were originally at 500,000, 75,000 of which vested in July 2020. An additional 75,000 RSU's vest upon FDA approval of the company's class III PMA, an additional 100,000 of the RSU's will vest on January 1, 2021 and the balance will vest upon the company achieving $20 million in gross cumulative sales or a covered transaction or Trigger event as defined in the agreement.

Remarks:

	/s/ Kristofer Heaton	01/06/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.